• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Farquhar John C.M.

    4/14/26 5:53:18 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Farquhar John C.M.

    (Last)(First)(Middle)
    C/O HEARTFLOW, INC.
    135 MAIN STREET, SUITE 1000

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Heartflow, Inc. [ HTFL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/10/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock04/10/2026S(1)22,562D$26.72549,163D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
    /s/ Nga Van, by power of attorney04/14/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $HTFL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL

    DatePrice TargetRatingAnalyst
    5/4/2026Outperform
    William Blair
    1/28/2026$38.00Overweight
    Wells Fargo
    9/2/2025$36.00Overweight
    Analyst
    9/2/2025$38.00Overweight
    Piper Sandler
    9/2/2025$35.00Buy
    Stifel
    9/2/2025$35.00Buy
    Canaccord Genuity
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Heartflow

    William Blair initiated coverage of Heartflow with a rating of Outperform

    5/4/26 8:35:19 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Heartflow with a new price target

    Wells Fargo initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    1/28/26 7:17:09 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lightcap Jeffrey C bought $1,053,680 worth of shares (40,000 units at $26.34) (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    12/17/25 6:43:50 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $261,266 worth of shares (9,219 units at $28.34) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    5/20/26 5:55:39 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farquhar John C.M. sold $657,005 worth of shares (22,562 units at $29.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 519,397 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    5/13/26 6:23:51 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Jones Marie L. covered exercise/tax liability with 567 units of Common Stock., decreasing direct ownership by 2% to 31,083 units (SEC Form 4) (withholding tax)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    5/8/26 6:47:10 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.

    SCHEDULE 13G/A - Heartflow, Inc. (0001464521) (Subject)

    5/15/26 4:30:03 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Heartflow Inc.

    10-Q - Heartflow, Inc. (0001464521) (Filer)

    5/14/26 4:31:12 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Heartflow, Inc. (0001464521) (Filer)

    5/14/26 4:03:21 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

    SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt

    5/14/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Future of Intoxication Detection May Be in Your Voice

    AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming

    5/11/26 8:30:00 AM ET
    $BFLY
    $HTFL
    $RXRX
    Medical Electronics
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    $HTFL
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes

    MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking GAMEFILM Registry. Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will now extend to include former players from the National Basketball Association (NBA) and the National Hockey League (NHL), broadening Heartflow's initiative to protect the heart health of professional athletes across major sports. Retired NBA star Muggsy Bogues was one of the first former professional basketball players to join the GAMEFILM

    2/12/26 8:00:00 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Financials

    Live finance-specific insights

    View All

    Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

    SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt

    5/14/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026

    SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live an

    4/23/26 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Total revenue of $49.1 million, a 40% increase year-over-yearGross margin of 79.5%, non-GAAP gross margin of 79.9%Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 millionU.S. installed base of 1,465 accounts as of December 31, 2025U.S. Plaque installed base of 489 accounts as of December 31, 2025Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives

    3/18/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care